Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Non-Inferiority Randomized Controlled Trial

NCT06064344 is registered in ClinicalTrials.gov with Zhongshan Ophthalmic Center, Sun Yat-sen University as lead sponsor.

NCT NCT06064344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06064344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Non-Inferiority Randomized Controlled Trial
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 7, 2023
Completion date
October 6, 2027
Enrollment
108 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary ocular adnexal malt lymphoma